Icon	Function
💬	A pop-up explanation appears when you mouse-over the text beside this icon. Also, an explanation window appears when you click this icon.
	The links beside this icon are links to external sites.
	Clicking this icon sorts the table by the item with this icon (Numerical or alphabetical order). Each click toggles between ascending and descending order.
	A text longer than 100 characters is fully displayed or collapsed.
	The contents of the displayed table are downloaded as a file named "table.csv".

DR info

Clinical trials : 41 / Drugs : 66 - (DrugBank : 30) / Drug target genes : 35 - Drug target pathways : 126

Drugs, Primary sponsors and Trial info (Enrollment year, Phase, Trial ID, Countries)

Adalimumab
   Chinese SLE Treatment And Research Group
      2025   Phase 4   NCT07013838   China
   Marmara University
      2025   -   NCT07491913   Turkey (Türkiye)
   Shanghai Zhongshan Hospital
      2024   Phase 4   NCT06498089   China
      2020   Phase 4   NCT04300686   China
Adalimumab injection
   Chinese SLE Treatment And Research Group
      2022   Phase 4   NCT05151848   China
ANTI-thymocyte globulin
   Fairview University Medical Center
      2000   -   NCT00006055   United States
Autologous peripheral blood stem cell transplantation
   Fairview University Medical Center
      2000   -   NCT00006055   United States
AZA
   Chinese SLE Treatment And Research Group
      2017   Phase 3   NCT03096275   China
Baricitinib 4 MG
   Liu Tian
      2023   Phase 2   NCT06662721   China
Bosentan and dapagliflozin
   University of Edinburgh
      2025   Phase 2   NCT06887062   United Kingdom
Certolizumab pegol
   Marmara University
      2025   -   NCT07491913   Turkey (Türkiye)
Clopidogrel
   Jose Carlos Nicolau
      2024   -   NCT06807788   Brazil
Computed tomography
   Jonsson Comprehensive Cancer Center
      2016   Early Phase 1   NCT02925351   United States
CYC
   Chinese SLE Treatment And Research Group
      2017   Phase 3   NCT03096275   China
Cyclophosphamide
   Fairview University Medical Center
      2000   -   NCT00006055   United States
Cyclosporine
   Fairview University Medical Center
      2000   -   NCT00006055   United States
Dengue 1,2,3,4 (attenuated) vaccine
   University of Sao Paulo General Hospital
      2026   Phase 4   NCT07087912   Brazil
Deucravacitinib
   Chinese SLE Treatment And Research Group
      2025   Phase 4   NCT07013838   China
Filgrastim
   Fairview University Medical Center
      2000   -   NCT00006055   United States
Fluorine F 18 clofarabine
   Jonsson Comprehensive Cancer Center
      2016   Early Phase 1   NCT02925351   United States
Genetic sequencing
   China National Center for Cardiovascular Diseases
      2017   -   NCT03199183   China
Glucocorticoids
   Chinese SLE Treatment And Research Group
      2017   Phase 3   NCT03096275   China
   Peking Union Medical College Hospital
      2026   Phase 4   ChiCTR2600121651   China
   Zhongshan hospital, Fudan University
      2026   Phase 4   ChiCTR2500114756   China
Glucorticoid taper regimen
   Janssen Pharmaceutical K.K.
      2021   Phase 3   NCT04882072   Japan
   Nishikawa Kazuko
      2021   Phase 3   JPRN-jRCT2061210007   -
Infliximab
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS
      2019   Phase 3   EUCTR2018-003753-13-FR   France
   Assistance Publique - Hôpitaux de Paris
      2020   Phase 2   NCT04564001   -
   Cambridge University Hospitals NHS Foundation Trust
      2021   Phase 2   NCT05168475   United Kingdom
   Marmara University
      2025   -   NCT07491913   Turkey (Türkiye)
   Ospedale San Raffaele
      2017   -   NCT03192878   Italy
Ivarmacitinib
   Chinese SLE Treatment And Research Group
      2026   Phase 4   NCT07451665   China
   Peking Union Medical College Hospital
      2026   Phase 4   ChiCTR2600121651   China
   Zhongshan hospital, Fudan University
      2026   Phase 4   ChiCTR2500114756   China
Laboratory biomarker analysis
   China National Center for Cardiovascular Diseases
      2017   -   NCT03199183   China
Leflunomide
   Jiang lindi
      2016   -   NCT02981979   China
   Shanghai Zhongshan Hospital
      2016   -   NCT03893136   China
Methotrexate
   Shanghai Zhongshan Hospital
      2024   Phase 4   NCT06498089   China
      2021   Phase 4   NCT05102448   China
Methotrexate tablets
   Shanghai Zhongshan Hospital
      2020   Phase 4   NCT04299971   China
Methylprednisolone
   Fairview University Medical Center
      2000   -   NCT00006055   United States
MMF
   Chinese SLE Treatment And Research Group
      2017   Phase 3   NCT03096275   China
MTX
   Chinese SLE Treatment And Research Group
      2017   Phase 3   NCT03096275   China
Naltrexone hydrochloride
   University of Pennsylvania
      2019   Phase 2   NCT03482479   Canada;United States
PET-CT
   China National Center for Cardiovascular Diseases
      2017   -   NCT03199183   China
Pirfenidone capsules
   Shanghai Zhongshan Hospital
      2025   Phase 4   NCT07325357   -
Positron emission tomography
   Jonsson Comprehensive Cancer Center
      2016   Early Phase 1   NCT02925351   United States
Prednisolone
   AbbVie
      2020   Phase 3   NCT04161898   Argentina;Brazil;China;Japan;South Korea;Turkey (Türkiye)
Prednisone
   Chinese SLE Treatment And Research Group
      2026   Phase 4   NCT07451665   China
   Fairview University Medical Center
      2000   -   NCT00006055   United States
   Shanghai Zhongshan Hospital
      2024   Phase 4   NCT06498089   China
Prednisone acetate tablets
   Jiang lindi
      2016   -   NCT02981979   China
Prednisone, cyclophosphamide
   Chinese Academy of Medical Sciences, Fuwai Hospital
      2018   Phase 2/Phase 3   NCT03550781   -
Rituximab
   Cambridge University Hospitals NHS Foundation Trust
      2021   Phase 2   NCT05168475   United Kingdom
Roactemra 20MG/ML
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS
      2019   Phase 3   EUCTR2018-003753-13-FR   France
Secukinumab
   Assistance Publique - Hôpitaux de Paris
      2026   Phase 2   NCT07477795   -
Tociliuzumab
   Marmara University
      2025   -   NCT07491913   Turkey (Türkiye)
Tocilizumab
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS
      2019   Phase 3   EUCTR2018-003753-13-FR   France
   Assistance Publique - Hôpitaux de Paris
      2020   Phase 2   NCT04564001   -
      2014   Phase 3   NCT02101333   France
   Cambridge University Hospitals NHS Foundation Trust
      2021   Phase 2   NCT05168475   United Kingdom
   Chugai Pharmaceutical Co., Ltd.
      2014   Phase 3   JPRN-jRCT2080222565   Japan
   Department of Cardiovascular Medicine Graduate School of Medicine Osaka University
      2012   -   JPRN-UMIN000007845   Japan
   Department of Rheumatology & Clinical Immunology Saitama Medical Center, Saitama Medical Universitity
      2012   -   JPRN-UMIN000008812   Japan
   Osaka University
      2017   -   JPRN-UMIN000025940   Japan
   Osaka Unversity
      2014   -   JPRN-UMIN000025943   Japan
   Shanghai Zhongshan Hospital
      2024   Phase 4   NCT06498089   China
      2020   Phase 4   NCT04300686   China
      2016   -   NCT03893136   China
Tofacitinib
   Shanghai Zhongshan Hospital
      2024   Phase 4   NCT06498089   China
      2021   Phase 4   NCT05102448   China
Tofacitinib 5 MG
   Chinese SLE Treatment And Research Group
      2022   Phase 4   NCT05151848   China
Tofacitinib tablet
   Shanghai Zhongshan Hospital
      2020   Phase 4   NCT04299971   China
Upadacitinib
   AbbVie
      2020   Phase 3   NCT04161898   Argentina;Brazil;China;Japan;South Korea;Turkey (Türkiye)
   AbbVie GK
      2020   Phase 3   JPRN-jRCT2080224967   Asia except Japan;Europe;Japan;South America
Ustekinumab
   Janssen Pharmaceutical K.K.
      2021   Phase 3   NCT04882072   Japan
   Nishikawa Kazuko
      2021   Phase 3   JPRN-jRCT2061210007   -
Usual medical management OF patients, additional blood and stool samples FOR biobanking
   Santé Arménie French-Armenian Research Center
      2023   -   NCT05904301   Armenia
Vanakizumab
   Chinese SLE Treatment And Research Group
      2026   Phase 4   NCT07451665   China
Vunakizumab
   Peking Union Medical College Hospital
      2026   Phase 4   ChiCTR2600121651   China
Yellow fever vaccine
   University of Sao Paulo General Hospital
      2018   -   NCT03430388   Brazil